BioSpace News Archive

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of an underwritten public offering of units for gross proceeds of $13.8 million,

Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2020 financial results at 6:00 am EDT on Tuesday, February 4, 2020.

A priority review voucher was submitted with the NDA, shortening the anticipated time for review.

Filing for ABP 798 Supported by Two Comparative Clinical Studies

Orapeutic, the company’s third FDA cleared product, has been developed to fight the current opioid epidemic that the healthcare industry is facing today.

CORE Pathways was Built for Sophisticated Predictive Analytics

The publication highlights the first-ever independent, multicenter study investigating the applicability of the Surfacer System, a novel approach to achieving right-sided, upper body central venous access in patients with obstructions or other conditions that preclude central venous access by conventional methods.

On Nov. 4, 2019, Jaycob was among the first patients in Florida to have his heart repaired using a next-generation medical device that offers a better option for closing ASDs.

Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which a single patient with GM1 gangliosidosis was administered investigational AXO-AAV-GM1 gene therapy

• First program from the Topas platform to enter clinical testing • TPM203 is one of several proprietary programs being developed by Topas • Pemphigus vulgaris is an orphan indication that currently has no cure